Testosterone Therapy and Atrial Fibrillation Risk: Reevaluating Safe Limits
On September 1, 2026, the Journal of the Endocrine Society published a structured narrative review by researchers from the University of Kansas detailing how testosterone replacement therapy influences the risk of atrial fibrillation. This comprehensive report synthesized recent clinical trials to evaluate cardiovascular safety parameters for middle aged and older men.
Assessing The Evidence
The researchers conducted a structured narrative review rather than initiating a new randomized clinical trial. The authors searched the MEDLINE, PubMed and Embase databases for evidence published through May 4, 2026. The research team also reviewed relevant conference abstracts, regulatory records, clinical guidelines and society statements. This broad search strategy allowed the authors to evaluate a wide spectrum of scientific literature. The final synthesis incorporated randomized trials, observational cohorts, laboratory research and previous statistical analyses.
The TRAVERSE Trial Parameters
A significant portion of the review focused on the landmark TRAVERSE trial. This randomized cardiovascular safety trial involved 5,246 men aged 45 to 80. Every participant had symptomatic hypogonadism alongside established cardiovascular disease or multiple cardiovascular risk factors. The study design required participants to register two fasting morning testosterone measurements below 300 ng/dL prior to enrollment.
Participants in the TRAVERSE trial received either a once daily 1.62% transdermal testosterone gel or a placebo. The researchers tracked these men across a mean treatment duration of 22 months. The mean follow up period for the study was 33 months. This allowed the original investigators to capture medium term cardiovascular outcomes.
Observational Cohorts
The review also analyzed several large scale observational studies to understand real world outcomes. One major inclusion was a post hoc analysis of the ASPREE study. This specific analysis followed 4,570 community dwelling older men for a median duration of 4.4 years. The ASPREE cohort provided valuable data on incident atrial fibrillation events among an aging male population.
The authors evaluated a large United States veterans cohort consisting of 76,639 men. This massive dataset offered a different perspective on therapy outcomes. The veterans cohort illustrated how the normalization of testosterone levels during therapy correlated with lower incident atrial fibrillation. By combining these distinct cohorts, the review team built a comprehensive picture of current clinical practices.
Previous Meta Analyses
The researchers incorporated data from a broad analysis of 106 placebo controlled randomized trials. This combined analysis involved 8,126 men receiving testosterone replacement therapy alongside 7,310 placebo participants. The large sample size provided substantial statistical power for evaluating major cardiovascular events. The review also referenced a separate long term statistical analysis published in late 2025.
Physiological Outcomes
The central conclusion of the review is that the association between testosterone and atrial fibrillation follows a U shaped curve. The researchers noted that atrial fibrillation risk appears higher at both low and high testosterone levels. Conversely, the lowest observed risk appears in the middle of the normal physiologic range. The paper proposes an approximate total testosterone target of 350 to 550 ng/dL to minimize this specific cardiovascular risk.
Cardiovascular Event Rates
The TRAVERSE trial data revealed specific cardiovascular event frequencies. Primary major adverse cardiovascular events occurred in 7.0% of testosterone treated participants, which equated to 182 events. In the placebo group, these events occurred in 7.3% of participants, totaling 190 events. The trial successfully met its prespecified noninferiority criterion for major adverse cardiovascular events.
While major events showed no increase, incident atrial fibrillation rates differed between the groups. Atrial fibrillation occurred in 3.5% of the testosterone treated participants. This represented 91 distinct events. In the placebo group, incident atrial fibrillation occurred in 2.4% of participants, representing 63 events. The review characterizes this difference as an approximately 50% relative excess for the treatment group.
The separate analysis of 106 placebo controlled trials found no statistically significant overall difference in major cardiovascular events. That analysis reported a Mantel Haenszel odds ratio of 1.44 for atrial fibrillation, with a 95% confidence interval spanning from 0.46 to 4.46. The late 2025 analysis similarly found no increase in all cause mortality, cardiovascular mortality, stroke or myocardial infarction. That 2025 analysis did note a higher rate of cardiac arrhythmias among treated men.
The ASPREE Hazard Ratios
The ASPREE study analysis provided specific risk calculations for older men. The researchers recorded 286 incident atrial fibrillation events during the follow up period. This corresponded to an incidence rate of 15.3 cases per 1,000 participant years. The analysis showed that atrial fibrillation risk nearly doubled in the two highest testosterone quintiles compared with the median quintile.
The reported hazard ratios for these upper quintiles were 1.91 and 1.98. The 95% confidence intervals for these ratios were 1.29 to 2.83 and 1.33 to 2.94 respectively. These figures support the observation that high normal testosterone levels correlate with higher incident risk. A separate analysis of the UK Biobank reportedly found higher incident risk at both ends of the testosterone distribution.
Proposed Biological Mechanisms
The authors proposed distinct biological explanations for the risks at either end of the testosterone spectrum. At low hormone levels, changes involving calcium handling may promote calcium leakage. This process involves specific proteins such as NCX, RyR2 and the late sodium current. These cellular changes can lead to delayed afterdepolarizations and triggered electrical activity.
At high hormone levels, the mechanisms shift toward potassium current alterations. Changes in potassium currents, including IK1, IKs and Ito, may shorten the atrial action potential duration. This shortening can also affect the effective refractory period. The researchers suggest these specific electrical changes potentially make atrial re entry easier.
Practical Implications for Treatment
The reviewed paper focuses heavily on treatment decisions for men with symptomatic hypogonadism rather than performance oriented hormone optimization. Men should not interpret fatigue, reduced gym performance, lower libido or negative changes in body composition as automatic proof of hormone deficiency. Accurate diagnosis requires thorough clinical assessment and appropriate morning laboratory testing. A man considering intervention should ask whether reversible contributors have been adequately addressed before starting a protocol. These reversible factors include obesity, heavy alcohol use, sleep disturbances and underlying metabolic disease.
The ultimate goal of treatment should be symptom improvement and restoration toward a physiologic baseline. Patients and clinicians should avoid pushing numbers to the highest achievable laboratory limit. The 350 to 550 ng/dL figure should serve as an evidence informed aspiration rather than a universal prescription or a guaranteed safe zone. Men with a history of palpitations, frequent premature beats or left atrial enlargement should discuss specific rhythm risks before escalating their therapy. The review authors recommend careful shared decision making for these higher risk groups.
Men experiencing sustained palpitations or an irregular pulse should seek immediate medical evaluation. The same urgency applies to fainting, chest pain, breathlessness or neurological symptoms. Patients should secure professional medical assessment rather than simply adjusting their hormone protocols independently.
Rajat S. Barua, a co author affiliated with the Kansas City Veterans Affairs Medical Center, stated that the dose and the target level matter. The authors discourage deliberately pushing symptomatic men toward upper normal levels between 700 and 1,000 ng/dL. The evidence does not establish additional symptomatic or metabolic benefit from targeting those higher numbers.
The review authors recommend calculating free testosterone when sex hormone binding globulin is abnormal. Total testosterone may not adequately represent hormone exposure under those specific conditions. The researchers identify hematocrit as the principal dose limiting safety constraint. They advise monitoring blood pressure and renal function alongside liver health. Clinicians should also track hematocrit and cardiac rhythm. For men with higher cardiovascular risk, the authors favor formulations with steadier pharmacokinetics over short acting preparations. Short acting injections may produce supraphysiologic peaks within 24 to 72 hours.
Structural Limitations
The researchers documented multiple structural limitations and methodological caveats within their review. Because the paper is a narrative review rather than a formal statistical analysis, the authors did not perform formal risk of bias scoring. The proposed mid range target of 350 to 550 ng/dL has not been prospectively tested as a validated prevention threshold. The Endocrine Society stresses that this range is an inference derived strictly from observational data.
Conflicting Data
The available observational literature is not uniformly aligned across all studied demographics. In the large United States veterans cohort, the normalization of testosterone during therapy actually correlated with lower incident atrial fibrillation. The authors stress that these conflicting findings prevent the proposed mid range target from acting as a proven prevention threshold. The studies reviewed differ significantly in their populations, treatment formulations, follow up periods and confounding adjustments.
The review authors also clarify that low testosterone might partially reflect existing health conditions rather than acting as an isolated cause of arrhythmia. Low hormone levels often correlate with obesity and diabetes. They also frequently present alongside hypertension, chronic illness or general frailty. The interaction between hormone therapy and established risk factors like age, sleep apnea, alcohol use and left atrial size remains poorly characterized. This lack of systematic characterization makes direct comparisons between clinical trials difficult.
Formulation Variables
The TRAVERSE trial tested only a 1.62% transdermal gel. The review explicitly states that these findings cannot automatically be applied to oral formulations, pellets or injectable variants like cypionate and enanthate. The newer oral products, including Jatenzo and Tlando, carry specific warnings concerning blood pressure elevation. These oral medications require dedicated blood pressure monitoring protocols.
The review does not establish that testosterone therapy causes a direct increase in stroke events. The primary TRAVERSE endpoint, which included nonfatal stroke, met noninferiority criteria. The review also does not prove that every man with naturally high testosterone must lower it. The evidence does not show that every man receiving therapy will face an increased risk of irregular heart rhythms. The safest interpretation is that appropriate therapy depends heavily on baseline risk, formulation choice, achieved levels and structured monitoring.
What This Changes
What this changes: This research alters current prescribing practices for men over 45 by demonstrating that cautious restoration to the middle of the physiologic range is clinically safer than pushing testosterone numbers to upper normal limits.
How Everfitguys helps
Automatically escalating hormone doses to chase upper reference limits often introduces unnecessary cardiovascular risks, but Everfitguys delivers the clinical context needed to balance therapeutic benefits against potential harm. Losing muscle, strength and physical capability with age frequently drives men toward aggressive treatments, so we provide objective reporting to help you restore normal function safely.
Sources
Stay sharp
Get stories
The best writing on craft and life, delivered once a week. No noise, just the good stuff.
